Methods of enhancing tumor immunogenicity using modified tumor cells and modified dendritic cells and compositions of autologous cancer immunotherapy products

摘要

The present specification describes, inter alia, methods of enhancing the antigen content of tumor associated antigens (TAAs) and the immunogenicity of cancer cells, methods of enhancing cross-presentation of dendritic cells, such methods derived from a single cancer patient. Compositions comprising engineered cells and methods of using these compositions as personal immunotherapy products to treat cancer in donor patients are provided. [Selection diagram] Fig. 1